USFDA concludes inspection of Indoco’s Rabale facility
May 20, 2024
Source: drugdu
112
Indoco Remedies announced that the United States Food and Drug Administration (USFDA) successfully completed inspection of its API Kilo Lab manufacturing facility at Rabale, Navi Mumbai and Indoco Analytical Solutions (IAS) division. The inspection concluded with zero Form 483 observations.
“We remain committed to ensuring the safety and efficacy of our products while maintaining the trust of our customers and stakeholders”, said Aditi Panandikar, MD, Indoco Remedies.
https://www.expresspharma.in/usfda-concludes-inspection-of-indocos-rabale-facility/
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Taking advantage of the “Eight Measures of Science and Technology”, Haier Health aims to create a flagship of biotechnology December 24, 2024
- Beware of “two sets of prices” providing funding sources for pharmaceutical bribery December 24, 2024
- Is placebo effective? Vertex evaporates $13 billion overnight December 24, 2024
- Aadi Biosciences and WuXi Biologics collaborate to develop 3 new ADC drugs December 24, 2024
- Novo Nordisk’s talent war December 24, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
